Oryn Therapeutics is a clinical-stage company developing a new class of drug candidates, Orynotides. These proprietary drug candidates are engineered, stable, cyclic peptides with very low immunogenicity and toxicity. They modulate pathologic inflammation and have proven effective in animal models of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis and ulcerative colitis. They have proven effective in preclinical cancer models and augment natural host defense, functioning as host-directed anti-infectives against drug resistant pathogens.